[Maintenance therapy with rituximab].
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006801:Humans; D008134:Long-Term Care; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000451:nursing*; D008224:Lymphoma, Follicular / Q000188:drug therapy / Q000451:nursing*; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy / Q000451:nursing*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000451:nursing*; D016032:Randomized Controlled Trials as Topic / Q000451:nursing; D012074:Remission Induction; D000069283:Rituximab; D016896:Treatment Outcome; D019139:Tumor Escape / Q000187:drug effects / Q000276:immunology
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab